TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28885428

Group type: EXPERIMENTAL
Intervention: Brief behavioral intervention during prenatal care visit (7‐ to 10‐minute in‐office intervention including a video and hygiene education using motivational interviewing, reminder calendar, and weekly text message reminders)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard care (a brochure)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Brief behavioral intervention
Number of subjects: 197
Study: 25332065

Group type: EXPERIMENTAL
Intervention: Mental practice
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 20
Study: 22915788

Group type: COMPARATOR
Intervention: Robotic ablation at 25 W for 30 s (R30)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Robotic ablation at 25 W for 60 s (R60)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual ablation at 30 W for 60 s
Number of subjects: 20
Study: 21335507

Group type: EXPERIMENTAL
Intervention: Lycopene (10 μg/dL increase)
Number of subjects: 3434

Group type: COMPARATOR
Intervention: Lycopene (10 μg/dL increase) in placebo arm
Number of subjects: 3434
Study: 19472387

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Kohonen and probabilistic neural network (KNN and PNN) analysis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Calibration of contrast enhancement curves by PNN
Number of subjects: 24
Study: 16954440

Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Epirubicin + Tamoxifen
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: CAIX expression
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Markers of hormone sensitivity (bcl2, ER, PgR)
Number of subjects: 183
Study: 15284501

Group type: EXPERIMENTAL
Intervention: Periradicular methylprednisolone (in combination with bupivacaine)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 34
Study: 11773888

Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg i.v. bolus on days 0 and 4)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Antithymocyte globulin (ATG) (15 mg/day i.v. for up to 14 days)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 138

Group type: COMPARATOR
Intervention: Antithymocyte globulin (ATG)
Number of subjects: 138
Study: 9460599

Group type: EXPERIMENTAL
Intervention: Leuzea tincture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leveton
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 8452344

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension (20 mg/kg of body weight per day in two divided doses)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Penicillin V suspension (50 mg/kg/day in three divided doses)
Number of subjects: 385
Study: 3899250

Group type: COMPARATOR
Intervention: Chemotherapy (n = 59)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Immunotherapy (n = 57)
Number of subjects: 178
Study: 27888255

Group type: EXPERIMENTAL
Intervention: Direct intervention effects on temptations for limiting high-fat foods
Number of subjects: 6516

Group type: EXPERIMENTAL
Intervention: Direct intervention effects on stage of change for limiting high-fat foods
Number of subjects: 6516
Study: 29933868

Group type: EXPERIMENTAL
Intervention: Withania somnifera root extract
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25875939

Group type: EXPERIMENTAL
Intervention: Microcurrent with transcutaneous electrodes and aerobic exercise (30 minutes on cycloergometer) in IG1
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Microcurrent with transcutaneous electrodes and aerobic exercise (30 minutes on cycloergometer) in IG2
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Microcurrent with percutaneous electrodes and aerobic exercise (30 minutes on cycloergometer) in IG3
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Microcurrent applied simultaneously with aerobic exercise (30 minutes on cycloergometer) in IG4
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo group (PG) with microcurrent device switched off
Number of subjects: 42
Study: 23682155

Group type: EXPERIMENTAL
Intervention: Dietary restriction and exercise (DR + E) for 6 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 27
Study: 21114380

Group type: EXPERIMENTAL
Intervention: Barnidipine up to 20 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) up to 25 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 29
Study: 20128377

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d for 8 weeks
Number of subjects: 149

Group type: COMPARATOR
Intervention: Routine treatment (calcium antagonists, ACEI, diuretics, beta-receptor blocker for 8 weeks)
Number of subjects: 149
Study: 17406887

Group type: EXPERIMENTAL
Intervention: Flywheel group (FW)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (Ctrl)
Number of subjects: 24
Study: 15183485

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT) with daily RT in 3-Gy fractions, total dose of 21 Gy.
Number of subjects: 95

Group type: COMPARATOR
Intervention: Sham radiotherapy (sham RT).
Number of subjects: 95
Study: 11354587

Group type: EXPERIMENTAL
Intervention: Consumer of mental health services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Person with severe mental illness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Person with schizophrenia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schizophrenic
Number of subjects: 0
Study: 8039950

Group type: EXPERIMENTAL
Intervention: Yogic exercises for 1 month
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physical training (PT) exercises for 1 month
Number of subjects: 10
Study: 3190131

Group type: EXPERIMENTAL
Intervention: Picolax given the day before irrigation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Enema regimen
Number of subjects: 2
Study: 30829067

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral therapy for insomnia (wCBT-I) coupled with general sleep education
Number of subjects: 35

Group type: COMPARATOR
Intervention: General sleep education alone (wait-list control)
Number of subjects: 35
Study: 31781700

Group type: EXPERIMENTAL
Intervention: Immediate implant placement with provisional or customised healing abutment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thin tissue phenotype
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Horizontal implant position
Number of subjects: 40
Study: 28054260

Group type: COMPARATOR
Intervention: High-speed handpiece (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (160 mJ; 3 Hz)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (260 mJ; 3 Hz)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (300 mJ; 3 Hz)
Number of subjects: 40
Study: 26092495

Group type: EXPERIMENTAL
Intervention: Sodium NO3(‐) (0.15 mmol NaNO3(‐) · kg(‐1))
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 17
Study: 22859712

Group type: EXPERIMENTAL
Intervention: Aliskiren (300 mg once daily)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Valsartan (320 mg once daily)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 68
Study: 21333871

Group type: EXPERIMENTAL
Intervention: Angle-supported phakic intraocular lens (pIOL) implantation
Number of subjects: 360
Study: 19890230

Group type: EXPERIMENTAL
Intervention: Ziprasidone (n=124)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo (n=41-66)
Number of subjects: 175
Study: 17022982

Group type: EXPERIMENTAL
Intervention: Ovulation induction in a chronic low-dose step-up FSH regimen
Number of subjects: 85
Study: 12620789

Group type: EXPERIMENTAL
Intervention: Medial posting of foot orthotics
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Custom-molding of foot orthotics
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of medial posting and custom-molding of foot orthotics
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 21
Study: 10854561

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 82

Group type: COMPARATOR
Intervention: 5-FU and LCV
Number of subjects: 82
Study: 9272405

Group type: COMPARATOR
Intervention: Otilonium bromide 120 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Otilonium bromide (combined doses of 80, 160, and 240 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Otilonium bromide (all doses)
Number of subjects: 16
Study: 7712918

Group type: EXPERIMENTAL
Intervention: Low dose cyclosporin A (CsA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide pulses (IV‐CTX)
Number of subjects: 30
Study: 3068846

Group type: EXPERIMENTAL
Intervention: Quinine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 0
Study: 30452004

Group type: EXPERIMENTAL
Intervention: Educational DVD
Number of subjects: 0
Study: 26335915

Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza vaccine (MF-59)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nonadjuvanted influenza vaccine
Number of subjects: 68
Study: 26286337

Group type: EXPERIMENTAL
Intervention: Stribild(®) (switch group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuation of existing regimen (no-switch group)
Number of subjects: 0
Study: 23066663

Group type: EXPERIMENTAL
Intervention: Oral PUVA
Number of subjects: 35

Group type: COMPARATOR
Intervention: Oral PUVA sol
Number of subjects: 35
Study: 20464480

Group type: EXPERIMENTAL
Intervention: Serum cholesterol levels
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Triglycerides with alcohol consumption
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Dietary cholesterol levels
Number of subjects: 302
Study: 18718735

Group type: EXPERIMENTAL
Intervention: Chemotherapy or radiotherapy
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Psychoneurological symptoms
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal symptoms
Number of subjects: 282

Group type: COMPARATOR
Intervention: Demographic and clinical variables
Number of subjects: 282
Study: 17161740

Group type: EXPERIMENTAL
Intervention: Aplisol
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Tubersol
Number of subjects: 1203
Study: 14535966

Group type: EXPERIMENTAL
Intervention: Active nasal continuous positive airway pressure (nCPAP) treatment
Number of subjects: 101

Group type: COMPARATOR
Intervention: Sham placebo (control)
Number of subjects: 101
Study: 10891987

Group type: EXPERIMENTAL
Intervention: Presymptomatic HD gene carriers (PSGCs)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Nongene carriers (NGCs)
Number of subjects: 216
Study: 8938176

Group type: EXPERIMENTAL
Intervention: Phenprocoumon treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no phenprocoumon)
Number of subjects: 49
Study: 8278667

Group type: EXPERIMENTAL
Intervention: Traditional bandwidth knowledge of results (BW KR)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Reversed bandwidth knowledge of results (BW KR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Yoked control groups
Number of subjects: 48
Study: 3571046

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg orally every 12 h on days 1‐7
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg orally every 12 h on days 6‐14
Number of subjects: 8
Study: 31267818

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 280
Study: 29247452

Group type: EXPERIMENTAL
Intervention: Autogenous platelet concentrate (APC) applied additionally in test defects
Number of subjects: 25

Group type: COMPARATOR
Intervention: Guided tissue regeneration (GTR) without APC in control defects
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Test sites with APC
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control sites without APC
Number of subjects: 25
Study: 27431050

Group type: EXPERIMENTAL
Intervention: 12-step facilitation
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Pre-randomization measures of perceived benefit of 12-step groups
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Pre-randomization 12-step attendance
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Pre-randomization perceived benefit and problem severity
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Pre-randomization perceived barriers to 12-step groups
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Pre-randomization involvement in self-help activities
Number of subjects: 471
Study: 22974466

Group type: EXPERIMENTAL
Intervention: Rotarix™ (two or three doses at 10 and 14 weeks)
Number of subjects: 4417

Group type: COMPARATOR
Intervention: Placebo (three doses at 6, 10, 14 weeks)
Number of subjects: 4417
Study: 20608066

Group type: EXPERIMENTAL
Intervention: Cytoflavin tablets
Number of subjects: 0
Study: 18207018

Group type: EXPERIMENTAL
Intervention: Non-specific immunomodulation therapy (IMT)
Number of subjects: 2426

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2426

Group type: EXPERIMENTAL
Intervention: Non-specific immunomodulation therapy (IMT) in patients with no history of previous myocardial infarction (n=919)
Number of subjects: 2426

Group type: EXPERIMENTAL
Intervention: Non-specific immunomodulation therapy (IMT) in patients with NYHA II heart failure (n=689)
Number of subjects: 2426
Study: 16014394

Group type: EXPERIMENTAL
Intervention: Positive group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12825173

Group type: EXPERIMENTAL
Intervention: GBS II-TT (3.6 micro g of CPS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: GBS III-TT (12.5 micro g of CPS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bivalent GBS II-TT/III-TT vaccine
Number of subjects: 75

Group type: COMPARATOR
Intervention: GBS II-TT or GBS III-TT monovalent vaccines
Number of subjects: 75
Study: 10662983

Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia (EA) with local anaesthetics (bupivacaine 0.125% or ropivacaine 0.2%) and fentanyl 4.5 microg/ml, flow rate 4-10 ml/h
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCA) with piritramid (bolus 2.5 mg, lock out 15 minutes, maximum of 25 mg/4 h, no background infusion)
Number of subjects: 50
Study: 8861830

Group type: EXPERIMENTAL
Intervention: Prrikweg gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 100
Study: 1634056

Group type: EXPERIMENTAL
Intervention: Intravenous vasoactive intestinal polypeptide (VIP) at doses of 1.5, 3, and 5 pmol.kg‐1.min‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beta-adrenergic agonist isoproterenol
Number of subjects: 10
Study: 3966411

Group type: EXPERIMENTAL
Intervention: Low fat plus SPE group (n = 13)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo group (n = 11)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low fat diet group (n = 12)
Number of subjects: 36
Study: 31337441

Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) combined with a specific rehabilitation program (RP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham-rESWT combined with a specific rehabilitation program (RP)
Number of subjects: 40
Study: 29765102

Group type: EXPERIMENTAL
Intervention: 800 mg oral CBD
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 30
Study: 26706862

Group type: EXPERIMENTAL
Intervention: Cyproheptadine (4 mg 3 times per day for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24906647

Group type: EXPERIMENTAL
Intervention: Videoconferencing
Number of subjects: 31

Group type: COMPARATOR
Intervention: Face-to-face interaction
Number of subjects: 31
Study: 22123705

Group type: EXPERIMENTAL
Intervention: Lersivirine coadministered with raltegravir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lersivirine coadministered with maraviroc
Number of subjects: 0
Study: 21186535

Group type: EXPERIMENTAL
Intervention: Treatment group (Leep combined with drugs)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 144

Group type: COMPARATOR
Intervention: Secondary high-risk HPV non-treatment group
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Primary high-risk HPV treatment group (Leep combined with drugs)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Surgical therapy (Leep)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Surgical + Drugs
Number of subjects: 144
Study: 18672632

Group type: EXPERIMENTAL
Intervention: Hand-sewn method
Number of subjects: 117

Group type: COMPARATOR
Intervention: Stapled method
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Hand-sewn method (small esophagus)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Stapled method (small esophagus)
Number of subjects: 117
Study: 15741571

Group type: EXPERIMENTAL
Intervention: biennial FOBT (delivered by mail)
Number of subjects: 26882

Group type: EXPERIMENTAL
Intervention: biennial FOBT (delivered by general practitioner or a screening facility)
Number of subjects: 26882

Group type: EXPERIMENTAL
Intervention: patient's choice of FOBT or 'once‐only' sigmoidoscopy
Number of subjects: 26882

Group type: EXPERIMENTAL
Intervention: 'once‐only' sigmoidoscopy
Number of subjects: 26882

Group type: EXPERIMENTAL
Intervention: sigmoidoscopy followed by biennial FOBT
Number of subjects: 26882
Study: 12879275

Group type: EXPERIMENTAL
Intervention: Long-term antibiotic therapy with doxycycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mycoplasma blood infection
Number of subjects: 0
Study: 10188068

Group type: EXPERIMENTAL
Intervention: Immediate access to therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Watching-waiting control group
Number of subjects: 0
Study: 7532074

Group type: EXPERIMENTAL
Intervention: Multimedia textbook (MMTB)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Traditional lecture
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Printed textbook
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 267
Study: 1942930

Group type: EXPERIMENTAL
Intervention: Intensified therapy consisting of rotation of 6 non cross‐resistant drug combinations with 12 different agents.
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Continuation of intensive therapy for poor responders (children with more than 10% blasts in the BM on day 28).
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Good responders (children with less than or equal to 10% blasts in the BM on day 28).
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Remission status on day 28 in high-risk patients above one year of age.
Number of subjects: 305
Study: 7006118

Group type: EXPERIMENTAL
Intervention: 1 g of cefuroxime plus 1 g of probenecid
Number of subjects: 178

Group type: COMPARATOR
Intervention: 5 x 10(6) units of benzyl penicillin plus 1 g of probenecid
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: 750 mg of cefuroxime plus 1 g of probenecid
Number of subjects: 178

Group type: COMPARATOR
Intervention: 1.5 g of cefuroxime alone
Number of subjects: 178
Study: 30802609

Group type: EXPERIMENTAL
Intervention: Concomitant CO2 insufflation (Con)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Subsequent CO2 insufflation (Sub)
Number of subjects: 95
Study: 27717057

Group type: EXPERIMENTAL
Intervention: Open access aftercare by breast care nurses (Intervention n = 56)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard breast clinic aftercare (Control n = 56)
Number of subjects: 112
Study: 26303188

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablets (FBTs)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Oral morphine (OM)
Number of subjects: 263
Study: 24424709

Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine
Number of subjects: 122

Group type: COMPARATOR
Intervention: Intramuscular haloperidol
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Intramuscular levomepromazine
Number of subjects: 122
Study: 22654195

Group type: EXPERIMENTAL
Intervention: Home-based level 3 testing followed by 1 wk of autoPAP
Number of subjects: 373

Group type: COMPARATOR
Intervention: In-laboratory studies (LAB)
Number of subjects: 373
Study: 18534491

Group type: EXPERIMENTAL
Intervention: Highly cross-linked polyethylene
Number of subjects: 54

Group type: COMPARATOR
Intervention: Traditional polyethylene
Number of subjects: 54
Study: 17327934

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Esomeprazole 80 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Esomeprazole (all doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mean 24-h median intragastric pH
Number of subjects: 40
Study: 15471182

Group type: EXPERIMENTAL
Intervention: Ganciclovir (Cymevene) for three months (combined intravenous and oral)
Number of subjects: 133
Study: 11577950

Group type: EXPERIMENTAL
Intervention: CHX‐Alc (0.2% chlorhexidine solution)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHX‐NaF (0.12% chlorhexidine plus 0.05% sodium fluoride)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CHX‐CPC‐Zn (0.05% chlorhexidine plus 0.05% cetylpyridinium chloride plus 0.14% zinc lactate)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no mouthrinse)
Number of subjects: 12